As of early 2026, a $10,000 investment in Pfizer (PFE) stock 10 years ago generated a total return of approximately 22% to 53%, significantly underperforming the S&P 500, which returned over 200% in the same period. While the stock price itself has seen minimal, sometimes negative, 10-year growth, the total return has been supported by a high dividend yield.
- Total Return (with Dividends): Over the last decade, PFE has delivered a total return of roughly 53%.
- Price Performance: The stock price has experienced significant volatility and is recently trading near decade lows, with some metrics showing a -6% to -0.08% return on price alone over 10 years.
- Dividends: A major component of the return is its dividend, with the company increasing its dividend at a 5% Compound Annual Growth Rate (CAGR) over the past decade. As of early 2026, the dividend yield is exceptionally high, often exceeding 7%.
- Outlook: Investors have been concerned about patent expirations and declining revenue from COVID-19 products, resulting in a "neutral" or "weak hold" consensus for the stock as of early 2026.
In summary, Pfizer has been a poor 10-year investment for capital appreciation but has functioned as an income-generating, high-yield stock with substantial dividends.
